Induction therapy of GP(Pomalidomide+Obinutuzumab）
IIT2025083
Phase 2 small_molecule active
Quick answer
Induction therapy of GP(Pomalidomide+Obinutuzumab） for Indolent Lymphoma is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Indolent Lymphoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active